FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of July 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
1. Holding(s) in Company
2. Blocklisting Interim Review
3. Holding(s) in Company
4. Holding(s) in Company
5. Holding(s) in Company
Enclosure No. 1
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 7 July 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 6 July 2006, Acambis received notification that, as of the close of business
on 4 July 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street,
New York, NY 10004, USA, was interested in a total of 6,415,049 ordinary shares
of 10p each, representing a 5.97% holding of Acambis' issued share capital.
Of these 6,415,049 shares:
a) the interest in 261,395 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman
Sachs Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of Goldman Sachs Securities (Nominees)
Limited;
c) the interest in 334,700 shares arose from an interest held by GS&Co, acting
as custodian of 167,350 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 5,815,654 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No. 2
SCHEDULE 5
BLOCKLISTING SIX MONTHLY RETURN
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1996 Approved Share Option Scheme
3. Period of return: From 01 January 2006 to 30 June 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
361,929
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
361,929
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1995 Savings-Related Share Option Scheme
3. Period of return: From 01 January 2006 to 30 June 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
74,925
5. Number of shares issued/allotted under scheme during period:
1,890
6. Balance under scheme not yet issued/allotted at end of period:
73,035
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
Acambis 1999 Share Option Plan
3. Period of return: From 01 January 2006 to 30 June 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
534,073
5. Number of shares issued/allotted under scheme during period:
20,930
6. Balance under scheme not yet issued/allotted at end of period:
513,143
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
OraVax 1990 Stock Incentive Plan
3. Period of return: From 01 January 2006 to 30 June 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
143,706
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
143,706
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
1. Name of company
Acambis plc
2. Name of scheme
OraVax 1995 Stock Incentive Plan
3. Period of return: From 01 January 2006 to 30 June 2006
4. Number and class of shares(s) (amount of stock/debt security) not issued
under scheme at end of last period:
104,179
5. Number of shares issued/allotted under scheme during period:
Nil
6. Balance under scheme not yet issued/allotted at end of period:
104,179
7. Number and class of share(s) (amount of stock/debt securities) originally
listed and the date of admission:
33,916,280 ordinary shares of 10p each
Date of admission: 30 November 1995
Please confirm total number of shares in issue at the end of the period in order
for us to update our records:
107,374,227
Contact for queries: Elizabeth Brown
Address: Acambis plc, Peterhouse Technology Park,
100 Fulbourn Road, Cambridge CB1 9PT
Name of person making return: Elizabeth Brown
Telephone: 01223 275300
Position of person making return: Company Secretary
Date of return: 7 July 2006
Enclosure No. 3
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 10 July 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 7 July 2006, Acambis received notification that, as of the close of business
on 5 July 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street,
New York, NY 10004, USA, was interested in a total of 6,528,414 ordinary shares
of 10p each, representing a 6.08% holding of Acambis' issued share capital.
Of these 6,528,414 shares:
a) the interest in 261,395 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman
Sachs Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of GSSN;
c) the interest in 334,700 shares arose from an interest held by GS&Co, acting
as custodian of 167,350 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 5,929,019 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No. 4
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 13 July 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 12 July 2006, Acambis received notification that, as of the close of business
on 10 July 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street,
New York, NY 10004, USA, was interested in a total of 6,383,332 ordinary shares
of 10p each, representing a 5.94% holding of Acambis' issued share capital.
Of these 6,383,332 shares:
a) the interest in 261,395 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman
Sachs Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of GSSN;
c) the interest in 334,700 shares arose from an interest held by GS&Co, acting
as custodian of 167,350 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 5,783,937 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No. 5
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 19 July 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 19 July 2006, Acambis received notification that, as of the close of business
on 17 July 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street,
New York, NY 10004, USA, was interested in a total of 6,838,317 ordinary shares
of 10p each, representing a 6.37% holding of Acambis' issued share capital.
Of these 6,838,317 shares:
a) the interest in 261,395 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman
Sachs Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of GSSN;
c) the interest in 334,700 shares arose from an interest held by GS&Co, acting
as custodian of 167,350 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 6,238,922 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275
300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 31 July 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.